Home >> Research Area >>Natural Products>>Triterpenoids>> Ganoderic acid C2

Ganoderic acid C2

CAS# 103773-62-2

Ganoderic acid C2

Catalog No. BCN3036----Order now to get a substantial discount!

Product Name & Size Price Stock
Ganoderic acid C2: 5mg $161 In Stock
Ganoderic acid C2: 10mg Please Inquire In Stock
Ganoderic acid C2: 20mg Please Inquire Please Inquire
Ganoderic acid C2: 50mg Please Inquire Please Inquire
Ganoderic acid C2: 100mg Please Inquire Please Inquire
Ganoderic acid C2: 200mg Please Inquire Please Inquire
Ganoderic acid C2: 500mg Please Inquire Please Inquire
Ganoderic acid C2: 1000mg Please Inquire Please Inquire

Quality Control of Ganoderic acid C2

Number of papers citing our products

Chemical structure

Ganoderic acid C2

3D structure

Chemical Properties of Ganoderic acid C2

Cas No. 103773-62-2 SDF Download SDF
PubChem ID 57396771 Appearance Powder
Formula C30H46O7 M.Wt 518.7
Type of Compound Triterpenoids Storage Desiccate at -20°C
Synonyms Lanost-8-en-26-oicacid;98296-48-1
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (2R,6R)-2-methyl-4-oxo-6-[(3S,5R,7S,10S,13R,14R,15S,17R)-3,7,15-trihydroxy-4,4,10,13,14-pentamethyl-11-oxo-1,2,3,5,6,7,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid
SMILES CC(CC(=O)CC(C)C(=O)O)C1CC(C2(C1(CC(=O)C3=C2C(CC4C3(CCC(C4(C)C)O)C)O)C)C)O
Standard InChIKey RERVSJVGWKIGTJ-RQLZKMEDSA-N
Standard InChI InChI=1S/C30H46O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21-23,32,34-35H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,22+,23+,28+,29-,30+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Ganoderic acid C2

The fruit body of Ganoderma lucidum

Biological Activity of Ganoderic acid C2

DescriptionGanoderic acid C2 has anti-inflammatory,and anti-tumor-promoting activities. Ganoderic acid C2 can inhibit histamine release, it also has inhibitory effects on the induction of Epstein-Barr Virus early antigen.
TargetsHistamine Receptor | Immunology & Inflammation related
In vitro

Structural characterization of minor metabolites and pharmacokinetics of ganoderic acid C2 in rat plasma by HPLC coupled with electrospray ionization tandem mass spectrometry.[Pubmed: 23312386]

J Pharm Biomed Anal. 2013 Mar 5;75:64-73.


METHODS AND RESULTS:
The metabolites and pharmacokinetics of Ganoderic acid C2 (GAC2), a bioactive triterpenoid in Ganoderma lucidum in rat plasma were investigated by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS). Totally, ten minor phase I metabolites of GAC2 were characterized after oral administration of GAC2, on the basis of their mass fragmentation pathways or direct comparison with authentic compounds by high-performance liquid chromatography coupled with diode array detection and electrospray ion trap tandem mass spectrometry (HPLC-DAD-ESI-MS(n)), and liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry (LC-ESI-IT-TOF/MS) methods. Moreover, a rapid and specific method for quantification of GAC2 in rat plasma after oral administration was developed by using a liquid-liquid extraction procedure and HPLC-ESI-MS/MS analysis.
CONCLUSIONS:
It is the first time to report the metabolites and pharmacokinetics of GAC2.

Protocol of Ganoderic acid C2

Kinase Assay

Inhibition of aldose reductase in vitro by constituents of Ganoderma lucidum.[Pubmed: 20379959 ]

Planta Med. 2010 Oct;76(15):1691-3.

CHCl(3) extract of the fruiting body of Ganoderma lucidum was found to show inhibitory activity on human aldose reductase in vitro. From the acidic fraction, potent human aldose reductase inhibitors, Ganoderic acid C2 (1) and ganoderenic acid A (2), were isolated together with three related compounds. It was found that the free carboxyl group of Ganoderic acid C2 and ganoderenic acid A is essential in eliciting the inhibitory activity considering the much lower activity of their methyl esters.

Structure Identification
Bioorg Med Chem Lett. 2011 Dec 15;21(24):7295-7.

Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors.[Pubmed: 22047696]

A series of lanostane-type triterpenoids, known as ganoderma acids were isolated from the fruiting body of Ganoderma lucidum. Some of these compounds were identified as active inhibitors of the in vitro human recombinant aldose reductase. To clarify the structural requirement for inhibition, some structure-activity relationships were determined.
METHODS AND RESULTS:
Our structure-activity studies of ganoderma acids revealed that the OH substituent at C-11 is an important feature and the carboxylic group in the side chain is essential for the recognition of aldose reductase inhibitory activity. Moreover, double bond moiety at C-20 and C-22 in the side chain contributes to improving aldose reductase inhibitory activity. In the case of Ganoderic acid C2, all of OH substituent at C-3, C-7 and C-15 is important for potent aldose reductase inhibition.
CONCLUSIONS:
These results provide an approach to understanding the structural requirements of ganoderma acids from G. lucidum for aldose reductase inhibitor. This understanding is necessary to design a new-type of aldose reductase inhibitor.

Ganoderic acid C2 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ganoderic acid C2 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ganoderic acid C2

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.9279 mL 9.6395 mL 19.279 mL 38.5579 mL 48.1974 mL
5 mM 0.3856 mL 1.9279 mL 3.8558 mL 7.7116 mL 9.6395 mL
10 mM 0.1928 mL 0.9639 mL 1.9279 mL 3.8558 mL 4.8197 mL
50 mM 0.0386 mL 0.1928 mL 0.3856 mL 0.7712 mL 0.9639 mL
100 mM 0.0193 mL 0.0964 mL 0.1928 mL 0.3856 mL 0.482 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Ganoderic acid C2

Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors.[Pubmed:22047696]

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7295-7.

A series of lanostane-type triterpenoids, known as ganoderma acids were isolated from the fruiting body of Ganoderma lucidum. Some of these compounds were identified as active inhibitors of the in vitro human recombinant aldose reductase. To clarify the structural requirement for inhibition, some structure-activity relationships were determined. Our structure-activity studies of ganoderma acids revealed that the OH substituent at C-11 is an important feature and the carboxylic group in the side chain is essential for the recognition of aldose reductase inhibitory activity. Moreover, double bond moiety at C-20 and C-22 in the side chain contributes to improving aldose reductase inhibitory activity. In the case of Ganoderic acid C2, all of OH substituent at C-3, C-7 and C-15 is important for potent aldose reductase inhibition. These results provide an approach to understanding the structural requirements of ganoderma acids from G. lucidum for aldose reductase inhibitor. This understanding is necessary to design a new-type of aldose reductase inhibitor.

Structural characterization of minor metabolites and pharmacokinetics of ganoderic acid C2 in rat plasma by HPLC coupled with electrospray ionization tandem mass spectrometry.[Pubmed:23312386]

J Pharm Biomed Anal. 2013 Mar 5;75:64-73.

The metabolites and pharmacokinetics of Ganoderic acid C2 (GAC2), a bioactive triterpenoid in Ganoderma lucidum in rat plasma were investigated by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS). Totally, ten minor phase I metabolites of GAC2 were characterized after oral administration of GAC2, on the basis of their mass fragmentation pathways or direct comparison with authentic compounds by high-performance liquid chromatography coupled with diode array detection and electrospray ion trap tandem mass spectrometry (HPLC-DAD-ESI-MS(n)), and liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry (LC-ESI-IT-TOF/MS) methods. Moreover, a rapid and specific method for quantification of GAC2 in rat plasma after oral administration was developed by using a liquid-liquid extraction procedure and HPLC-ESI-MS/MS analysis. It is the first time to report the metabolites and pharmacokinetics of GAC2.

Description

Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 exhibits high inhibitory activity against the rat lens aldose reductase (RLAR) with an IC50 of 3.8 µM.

Keywords:

Ganoderic acid C2,103773-62-2,Lanost-8-en-26-oicacid;98296-48-1,Natural Products, buy Ganoderic acid C2 , Ganoderic acid C2 supplier , purchase Ganoderic acid C2 , Ganoderic acid C2 cost , Ganoderic acid C2 manufacturer , order Ganoderic acid C2 , high purity Ganoderic acid C2

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: